Background: T cell exhaustion (TEX) is an important immune escape mechanism, and an in-depth understanding of it can help improve cancer immunotherapy. However, the prognostic role of TEX in malignant lung adenocarcinoma (LUAD) remains unclear.Methods: Through TCGA and GEO datasets, we enrolled a total of 498 LUAD patients. The patients in TCGA-LUAD were unsupervised clustered into four clusters according to TEX signaling pathway. WGCNA analysis, survival random forest analysis and lasso regression analysis were used to select five differentially expressed genes among different clusters to construct a TEX risk model. The risk model was subsequently validated with GEO31210. By analyzing signaling pathways, immune cells and immune checkpoints...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
Background: T cell exhaustion (TEX) is an important immune escape mechanism, and an in-depth underst...
Abstract T-cell exhaustion (Tex) is considered to be a reason for immunotherapy resistance and poor ...
Despite the recent increase in the use of immune checkpoint blockade (ICB), no ICB medications have ...
Lung adenocarcinoma (LUAD) is the most common type of lung cancer and the leading cause of cancer in...
Despite the recent increase in the use of immune checkpoint blockade (ICB), no ICB medications have ...
Despite the recent increase in the use of immune checkpoint blockade (ICB), no ICB medications have ...
There is still no ideal predictive biomarker for immunotherapy response among patients with non-smal...
Lung adenocarcinoma (LUAD) is the most common type of lung cancer and the leading cause of cancer in...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
Patients with stage III lung adenocarcinoma (LUAD) have significant survival heterogeneity, meanwhil...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
Background: T cell exhaustion (TEX) is an important immune escape mechanism, and an in-depth underst...
Abstract T-cell exhaustion (Tex) is considered to be a reason for immunotherapy resistance and poor ...
Despite the recent increase in the use of immune checkpoint blockade (ICB), no ICB medications have ...
Lung adenocarcinoma (LUAD) is the most common type of lung cancer and the leading cause of cancer in...
Despite the recent increase in the use of immune checkpoint blockade (ICB), no ICB medications have ...
Despite the recent increase in the use of immune checkpoint blockade (ICB), no ICB medications have ...
There is still no ideal predictive biomarker for immunotherapy response among patients with non-smal...
Lung adenocarcinoma (LUAD) is the most common type of lung cancer and the leading cause of cancer in...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
Patients with stage III lung adenocarcinoma (LUAD) have significant survival heterogeneity, meanwhil...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...